New approval establishes era of ‘tissue-agnostic’ drugs

New Era of Lipid-Lowering Drugs.

There are several established lipid-modifying agents, including statins, fibrates, niacin, and ezetimibe, that have been shown in randomized clinical outcome trials to reduce the risk of having an atherosclerotic cardiovascular event. However, in many people, the risk of having an event remains unacceptably high despite treatment with these established agents. This has stimulated the search for...

New Era in Health Care: Tissue Engineering

Tissue engineering is a rapidly expanding field, which applies the principles and methods of physical sciences, life sciences and engineering to understand physiological and pathological systems and to modify and create cells and tissues for therapeutic applications. It has emerged as a rapidly expanding 'interdisciplinary field' that is a significant potential alternative wherein tissue and or...

Women and Drugs: A New Era for Research, 65

NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination...

Entering a New Era – Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T

Drug approval decision times, international reference pricing and strategic launches of new drugs

This paper analyzes how drug approval procedures in uence the incentives of pharmaceutical rms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a rm commercializes a new drug is larger when countries do not approve this new drug simultaneously. We also show that a rm's best response to international reference pricing is to...